Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (ANAB)
NASDAQ:ANAB
ANAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.21 - $41.31
Previous CloseN/A
Volume154.73K
Average Volume (3M)916.84K
Market Cap
$632.35M
Enterprise Value$387.22M
Total Cash (Recent Filing)$22.19M
Total Debt (Recent Filing)$4.92M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
May 08, 2025EPS Estimate
-1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.20
Shares Outstanding30,666,780
10 Day Avg. Volume889,196
30 Day Avg. Volume916,843
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.74
Price to Cash Flow (P/CF)-2.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.24
Enterprise Value/Ebitda-4.18
Forecast
1Y Price Target
$43.00Price Target Upside99.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
AnaptysBio News
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceANAB reported $43.1M in revenue, well above estimates, driven by commercial milestones from GSK’s Jemperli sales.
Pipeline DevelopmentANAB's pipeline includes promising candidates such as a CD122 antagonist and BDCA2 modulator.
Share RepurchaseANAB announced plans to repurchase up to $75M in shares, which represents roughly 12% of the primary shares outstanding.
Bears Say
Clinical Trial ResultsANAB announced that the Ph. IIb trial of ANB032 did not meet the primary EASI-75 endpoint nor any secondary endpoints and will discontinue further development.
Market CompetitionAnticipated Keytruda and Opdivo biosimilar launches in 2028 could introduce competitive pressures impacting Jemperli’s growth trajectory beyond 2028.
Program TerminationShares were pressured following LLY's termination of its PD-1 agonist program in RA.
---
Ownership Overview
43.85% Insiders
21.76% Mutual Funds
0.91% Other Institutional Investors
22.15% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANAB FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $12.21 and its highest was $41.31 in the past 12 months.
What is AnaptysBio Inc’s market cap?
AnaptysBio Inc’s market cap is $632.35M.
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is May 08, 2025 which is in 15 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on Feb 27, 2025. The company reported -$0.72 earnings per share for the quarter, beating the consensus estimate of -$1.619 by $0.899.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is -1.25.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 30,666,780 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of -$0.72 in its last earnings report, beating expectations of -$1.619. Following the earnings report the stock price went up 2.561%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Currently, no hedge funds are holding shares in ANAB
---
AnaptysBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.00 (99.26% Upside)
$43.00 (99.26% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.76%
12-Months-Change
Fundamentals
Return on Equity
-182.71%
Trailing 12-Months
Asset Growth
6.95%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc. (ANAB) is a clinical-stage biotechnology company focused on the discovery and development of novel antibody product candidates for the treatment of inflammatory diseases. The company leverages its proprietary antibody discovery technology platform to create therapeutic antibodies aimed at modulating immune system pathways. AnaptysBio's core products are primarily in the areas of immunology, with a strong emphasis on conditions with unmet medical needs.
---
ANAB Stock 12 Month Forecast
Average Price Target
$43.00
▲(99.26% Upside)
Technical Analysis
Best Analysts Covering ANAB
1 Year
1 Year Success Rate
9/16 ratings generated profit
1 Year Average Return
-14.02%
reiterated a buy rating 2 months ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of -14.02% per trade.
---